ProCE Banner Activity

Oral SERDs and Novel Endocrine Therapies: Reshaping the Treatment Landscape for ER+/HER2- Breast Cancer


Download this slideset from a live symposium to learn the latest data on oral SERDs and other novel endocrine therapies that are changing the treatment landscape for patients with ER+/HER2- breast cancer.

Released: December 01, 2023



Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from AstraZeneca.